Copper Is Tight, Silver Is Rising - And This Early Nevada Play Hits the Timing Perfectly
AI, electrification, battery storage, and data centers are pushing copper and silver demand sharply higher, even as supply stays tight. This region in Nevada offers rare multi-metal potential, and a new company has secured land in a district the surging district. It's one of the cleanest timing setups in the sector right now.
Shares Stats
| Shares Outstanding | 3,159,200,000 |
| Shares Float | 3,159,200,000 |
| Shares Short | 10,640,000 |
| Insider Holdings | 1% |
| Institution Holdings | 2.72% |
About Takeda Pharmaceutical Co ADR
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.
General
| Name | Takeda Pharmaceutical Co ADR |
| Ticker | TAK |
| Exchange | NYSE |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Currency | USD |
| Country | USA |
| Fiscal Year End | March |
| Full Time Employees | 47,455 |
Highlights
| Analyst Target | 15.99 |
| Market Cap | 45,208,200,000 |
| PE Ratio | 181.60 |
| PEG Ratio | 0.31 |
| EBITDA | 1,138,373,033,984 |
Financials
| Profit Margin | 0.87% |
| Operating Margin | 11.06 |
| Return on Assets | 0.02 |
| Return on Equity | 0.00 |
| Revenue | 29.6B |
| Earnings Per Share | 0.07 |
| Revenue Per Share | 1,400.91 |
| Gross Profit | 2,862,113,882,112 |
| Quarterly Revenue Growth | -0.05 |
Valuation
| Trailing PE | 204.43 |
| Forward PE | 10.06 |
| Price/Sales (Trailing 12 Mt.) | 0.01 |
| Price/Book (Most Recent Quarter) | 0.99 |
Dividend
Takeda Pharmaceutical Co ADR pays out a dividend of $0.65 per share, with a dividend yield of 4.54%.
TAK's last dividend payment was made to shareholders on July 7, 2025.
They pay out 242.25% of their earnings out as a dividend.
Recent Dividends
| Dec 31, 1969 | $0.32 |
| Jul 7, 2025 | $0.34 |
| Dec 12, 2024 | $0.33 |
| Jul 8, 2024 | $0.30 |
Marjorie Taylor Greene Goes Bargain Shopping, Discloses Buying These Two Stocks At 52-Week Lows
Congresswoman Marjorie Taylor Greene disclosed some new stocks recently. Unlike past trades in 2024 and 2025, the latest disclosure is rather unique.
Jim Cramer's '10 Stocks To Own For The Future' In 2000 Cost This Redditor A Decade Of Retirement, Says Having To Work 10 More Years Was 'Painful'
A Reddit user slammed Jim Cramer's stock picks at the peak of the Dot-Com bubble, saying that the CNBC host's suggestions cost him a decade of retirement.
The $43B Big Pharma Story is Starting Over-With a New Player - Ad
Big Pharma once paid $43B for a small biotech with a similar platform. Now, a new company is following that same playbook, leveraging its patented delivery technology to attract partnerships and near-term revenue potential.
Officer Injured By January 6 Predicts Trump Will Flee US After 2026 Elections: 'He'll Be Hopping on That Qatari Jet to Saudi Arabia'
Former District of Columbia Metro police officer Michael Fanone has speculated that President Trump might leave the U.S. after the 2026 elections.
Trump-Pardoned Ponzi Schemer Faces 37-Year Sentence For $44 Million COVID Scam
A previously convicted Ponzi schemer who had received a pardon from President Trump is heading back to prison due to involvement in a new fraudulent scheme.
The Smart Money Copper Trade - Ad
Quebec discovery. Strong grades. Roads and hydro in place. Funding secured for a busy drill calendar. Each assay can build scale and tighten the window for early entries as EVs and data centers pull harder on copper. Do not wait.
AT&T reached a $177M data breach settlement. What consumers should know about claiming their money
NEW YORK (AP) — AT&T has reached a combined $177 million settlement over two . And impacted consumers have a little over a month left to file a claim for their chunk of the money.
Scaramucci Says This One US Mistake Helped China Become a Manufacturing Superpower
Anthony Scaramucci recently highlighted what he considers a significant error by the US that enabled China to ascend as a manufacturing superpower.
They've Done It 20+ Times-Now They've Found a New Memecoin to Watch - Ad
Our analysts have built one of the most reliable track records in the memecoin space by recognizing early momentum signals many traders overlook. Their newest pick shows several of the same early indicators found in past standout performers. Get the details before this story spreads.
Senator Buys Coca-Cola, Hershey's Stock After Selling Magnificent Seven Stocks In 2025
A U.S. senator has bought three new stocks in November, his first buys in 2025. Here's the stocks he bought.
Nvidia, Dell, Coinbase, Gorilla Technology And Archer Aviation: Why These 5 Stocks Are On Investors' Radars Today
U.S. stocks closed lower on Monday, with the Dow slipping 1.2% to 46,590.24, the S&P 500 easing 0.92% to 6,672.41, and the Nasdaq dipping 0.84% to 22,708.07. These are the top stocks that gained the attention of retail traders and investors through the day:
Utility Over Hype: ETF Launch Alert - Ad
This ETF isn't about speculation, it's about infrastructure. Seconds-level settlement, low fees, and institutional custody.
Why Is Symbotic (SYM) Stock Trending Overnight?
Symbotic shares are moving higher overnight following after-hours trading gains and recent analyst and insider activity.
US air travelers without REAL IDs will be charged a $45 fee
Air travelers in the U.S. without a will be charged a $45 fee beginning in February, the Transportation Security Administration announced Monday.
The Repeatable Strategy Behind 20+ Early Memecoin Wins (Revealed) - Ad
Few analysts have been able to consistently spot strong memecoin setups, but our team has developed a repeatable framework that has helped them identify high-momentum plays early. Now they've uncovered a new project showing similar characteristics, and they want you to see the full breakdown yourself.
Warren Buffett Initiates Alphabet Position, Trims Apple In Q3 — Here Are Berkshire's Moves
Warren Buffett's Berkshire Hathaway took a new stake in a member of the Magnificent Seven, while lowering its stake in Apple in the third quarter.
Peter Schiff Says Bitcoin Buyers Have Only One (Unlikely) Hope To Bail Them Out
Bitcoin's (CRYPTO: BTC) slide through key support levels has brought long-time critic and gold advocate Peter Schiff back into the spotlight—and he's
$270,000 Drug. One Competitor. Billion-Dollar Market. - Ad
Phase 3 trial targets recurrent pericarditis with an oral therapy that could disrupt the only approved treatment. And their heart failure program launches in 2026.
Trump's Approval Rating Hits Lowest Since Returning To Office, With Support Falling Among Republicans, Independents
Trump's approval rating hits new low as Republican and independent support drops. Economy, immigration, and budget handling are major concerns.
Jeff Bezos Says Almost Everyone Focuses On What The Next 10 Years Will Look Like—Here's What People Should Ask Instead
Amazon's latest surge in AWS growth and AI focus suggests that Jeff Bezos' long-standing philosophy of building around unchanging customer needs is continuing to shape the company's success more than a decade later.
D.C.'s Quiet Plan for a New Tech Era - Ad
Why did federal agencies receive orders to "clear the runway" for a phenomenon most Americans haven't even heard of yet? And why are billionaires rushing in weeks before January 1? Whitney Tilson decoded the pattern.
Scrapyard workers recount horrific scene after UPS plane crash destroyed their Kentucky business
LOUISVILLE, Ky. (AP) — Supervisor Adam Bowman was loading metal onto a truck at a scrapyard just south of the Louisville, Kentucky, airport when he heard what he first thought was a transformer explosion and quickly realized was more horrific.
Walmart raises profit expectations as more Americans hunt deals in sluggish economy
NEW YORK (AP) — Walmart delivered another standout quarter, posting strong sales and profits that blew past Wall Street expectations as it wins over more cash-strapped Americans who have grown increasing anxious about the economy.
Weiss Gold Veteran Makes Shocking New Call - Ad
Weiss expert Sean Brodrick went out on a limb last year and declared a historic event would send the yellow metal to $3,150. People laughed at him at the time, but he was off by just two days. Now, Sean has a shocking new prediction for gold ... and reveals a little-known way to get ahead of this bull market.
Asian shares retreat in cautious trading ahead of Nvidia profit report
TOKYO (AP) — Asian shares retreated in cautious trading Wednesday ahead of an earnings report from that is seen as a bellwether for the recent craze for artificial intelligence technology.
Trump Asks Sanae Takaichi Not To Provoke China After Japan PM Hinted At Military Action Over Taiwan Invasion
Trump urges Japan's PM not to provoke China over Taiwan. Tensions rise as Japan refuses to retract remarks about possible military action.
The Next ETF Era Begins with Payments - Ad
After Solana and Hedera, another digital-asset ETF has arrived and it targets global money movement.
Tesla Wants To Shift Away From China-Made Components For US Cars: Report
Tesla requires suppliers to exclude Chinese parts for US car production. Despite challenges, aim to switch all parts within 1-2 years.
Meta Allegedly Concealed Evidence Of Social Media Harm, According To Court Filings: Report
Meta Platforms Inc. allegedly hid evidence of social media harm by shutting down a study on Facebook and Instagram's impact on mental health.
Copper Is Tight, Silver Is Rising - And This Early Nevada Play Hits the Timing Perfectly - Ad
AI, electrification, battery storage, and data centers are pushing copper and silver demand sharply higher, even as supply stays tight. This region in Nevada offers rare multi-metal potential, and a new company has secured land in a district the surging district. It's one of the cleanest timing setups in the sector right now.
Trump Rolls Back Tariffs On Coffee, Beef And More As Price Debate Heats Up— Here's What You Need To Know
President Donald Trump signed an executive order on Friday that retroactively lowers tariffs on beef, coffee, bananas, and tomatoes, among other agricultural imports.
BellRing Brands: No Ringing The Bell On This One, Not Yet
Our analysis uncovers the real reason behind BellRing Brands' steep fall and why the stock may struggle for much longer.
The $43B Big Pharma Story is Starting Over-With a New Player - Ad
Big Pharma once paid $43B for a small biotech with a similar platform. Now, a new company is following that same playbook, leveraging its patented delivery technology to attract partnerships and near-term revenue potential.
Trump's $2,000 Tariff Checks Gain Steam As Sen. Katie Britt Says Senate Should 'Take A Look' Amid Soaring 18% Consumer Tariff Burden
Momentum building for Trump's push for $2,000 tariff-funded payments as GOP lawmakers express openness. Treasury Sec. suggests income limits.
Trump Hints At Tax Cut, John Bolton Warns Of Peace Prize Ambitions And More: This Week in Politics
Trump hints at major income tax cuts, while political tensions rise over military orders, Russia policy, and government shutdown threats.
The Smart Money Copper Trade - Ad
Quebec discovery. Strong grades. Roads and hydro in place. Funding secured for a busy drill calendar. Each assay can build scale and tighten the window for early entries as EVs and data centers pull harder on copper. Do not wait.
IRS boosts contribution limits for 401(k) retirement plan savers
Americans will be allowed to contribute more of their money to 401(k) and similar retirement saving plans next year.
Meta alerts young Australians to download their data before a social media ban
MELBOURNE, Australia (AP) — Technology giant on Thursday began sending thousands of young Australians a two-week warning to downland their digital histories and delete their accounts from Facebook, Instagram and Threads before a world-first on accounts of children younger than 16 takes effect.
They've Done It 20+ Times-Now They've Found a New Memecoin to Watch - Ad
Our analysts have built one of the most reliable track records in the memecoin space by recognizing early momentum signals many traders overlook. Their newest pick shows several of the same early indicators found in past standout performers. Get the details before this story spreads.
Sarepta Shares Jump After FDA Approves Updated Elevidys Label
Sarepta Therapeutics shares jumped after the FDA issued a new boxed warning for Elevidys.
Information, charts or examples are for illustration and educational purposes only and not for individualized investment management This message contains commercial elements, such as advertising. We only send these offers to those who have opted in to our newsletter. Past performance is not indicative of future results. For these reasons we strongly suggest trading in a DEMO/Simulated account. The information provided by us is for educational and informational purposes only. We make no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended and have not determined if the statements and opinions of the advertiser are accurate, correct or truthful. If you use, act upon or make decisions in reliance on information contained or any external source linked within it, you do so at your own peril and agree to hold us, our officers, directors, shareholders, affiliates and agents without fault.